{
  "pmcid": "11076394",
  "sha256": "ec54673d49a24c38b831c0780c83943423a10de099d1af0f667ea438e9fd1c6a",
  "timestamp_utc": "2025-11-09T23:12:28.749797+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.084545454545456,
    "reading_ease": 35.022272727272764,
    "word_count": 240
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "NEPAFOX: A Randomised Controlled Trial of Perioperative FOLFIRINOX in Resectable Pancreatic Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomized patients with histologically confirmed resectable or borderline resectable pancreatic adenocarcinoma"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with histologically confirmed resectable or borderline resectable pancreatic adenocarcinoma, without metastases"
      },
      "Intervention": {
        "score": 2,
        "evidence": "upfront surgery followed by adjuvant gemcitabine (arm A) or perioperative FOLFIRINOX (arm B)"
      },
      "Objective": {
        "score": 1,
        "evidence": "The NEPAFOX trial aimed to assess the efficacy and safety of perioperative FOLFIRINOX compared to standard adjuvant gemcitabine"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary endpoint was overall survival (OS)"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was conducted using an interactive web response system with permuted blocks, stratified by ECOG performance status and resectability"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label trial"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "40 patients were randomized (arm A: 21, arm B: 19)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intention-to-treat population"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "median OS was 25.68 months (95% CI 11.74, –) in arm A and 10.03 months (95% CI 6.25–27.95) in arm B"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events grade ≥3 were higher in arm B (84% vs. 57%)"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered with ClinicalTrials.gov (NCT02172976)"
      },
      "Funding": {
        "score": 1,
        "evidence": "The trial was funded by institutional sources"
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}